Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease

Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease

Neuromuscular disorders such as Duchenne Muscular Dystrophy and Spinal Muscular Atrophy are neurodegenerative genetic diseases characterized primarily by muscle weakness and wasting. Until recently there were no effective therapies for these conditions, but antisense oligonucleotides, a new class of...

Full description

Bibliographic Details
Main Authors:	Valentina Sardone, Haiyan Zhou, Francesco Muntoni, Alessandra Ferlini, Maria Sofia Falzarano
Format:	Article
Language:	English
Published:	MDPI AG 2017-04-01
Series:	Molecules
Subjects:	Duchenne Muscular Dystrophy Spinal Muscular Atrophy antisense oligonucleotides clinical trials oligonucleotides delivery
Online Access:	http://www.mdpi.com/1420-3049/22/4/563

Similar Items

Targeting TGF-β Signaling by Antisense Oligonucleotide-mediated Knockdown of TGF-β Type I Receptor
by: Dwi U Kemaladewi, et al.
Published: (2014-01-01)

Recent advances in antisense oligonucleotide therapy in genetic neuromuscular diseases
by: Ashok Verma
Published: (2018-01-01)

Altered Levels of MicroRNA-9, -206, and -132 in Spinal Muscular Atrophy and Their Response to Antisense Oligonucleotide Therapy
by: Francesco Catapano, et al.
Published: (2016-01-01)

Preclinical Studies on Intestinal Administration of Antisense Oligonucleotides as a Model for Oral Delivery for Treatment of Duchenne Muscular Dystrophy
by: Maaike van Putten, et al.
Published: (2014-01-01)

Novel Cationic Carotenoid Lipids as Delivery Vectors of Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy
by: Vassilia Partali, et al.
Published: (2012-01-01)

Fructose Promotes Uptake and Activity of Oligonucleotides With Different Chemistries in a Context-dependent Manner in mdx Mice
by: Limin Cao, et al.
Published: (2016-01-01)

Efficient SMN Rescue following Subcutaneous Tricyclo-DNA Antisense Oligonucleotide Treatment
by: Valérie Robin, et al.
Published: (2017-06-01)

Long-term Exon Skipping Studies With 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models
by: Christa L Tanganyika-de Winter, et al.
Published: (2012-01-01)

Correlating In Vitro Splice Switching Activity With Systemic In Vivo Delivery Using Novel ZEN-modified Oligonucleotides
by: Suzan M Hammond, et al.
Published: (2014-01-01)

Evaluation of Amphiphilic Peptide Modified Antisense Morpholino Oligonucleotides In Vitro and in Dystrophic mdx Mice
by: Mingxing Wang, et al.
Published: (2017-05-01)

Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy
by: Alberto Malerba, et al.
Published: (2012-01-01)

High Concentration of an ISS-N1-Targeting Antisense Oligonucleotide Causes Massive Perturbation of the Transcriptome
by: Eric William Ottesen, et al.
Published: (2021-08-01)

Innovative Therapeutic Approaches for Duchenne Muscular Dystrophy
by: Fernanda Fortunato, et al.
Published: (2021-02-01)

Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients
by: Lars Hendrik Müschen, et al.
Published: (2021-02-01)

Context Dependent Effects of Chimeric Peptide Morpholino Conjugates Contribute to Dystrophin Exon-skipping Efficiency
by: HaiFang Yin, et al.
Published: (2013-01-01)

Exon-Skipping Oligonucleotides Restore Functional Collagen VI by Correcting a Common COL6A1 Mutation in Ullrich CMD
by: Sara Aguti, et al.
Published: (2020-09-01)

Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy
by: Haiyan Zhou, et al.
Published: (2020-06-01)

Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment
by: Corinne Betts, et al.
Published: (2012-01-01)

Peptide Nucleic Acid Promotes Systemic Dystrophin Expression and Functional Rescue in Dystrophin-deficient mdx Mice
by: Xianjun Gao, et al.
Published: (2015-01-01)

New Directions for SMA Therapy
by: Sonia Messina
Published: (2018-08-01)

Targeting the 5′ untranslated region of SMN2 as a therapeutic strategy for spinal muscular atrophy
by: Audrey M. Winkelsas, et al.
Published: (2021-03-01)

Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice
by: Dominic Jauvin, et al.
Published: (2017-06-01)

2′-O-Methyl RNA/Ethylene-Bridged Nucleic Acid Chimera Antisense Oligonucleotides to Induce Dystrophin Exon 45 Skipping
by: Tomoko Lee, et al.
Published: (2017-02-01)

Nanomedicine for Gene Delivery and Drug Repurposing in the Treatment of Muscular Dystrophies
by: Ilaria Andreana, et al.
Published: (2021-02-01)

A Short Antisense Oligonucleotide Ameliorates Symptoms of Severe Mouse Models of Spinal Muscular Atrophy
by: Jeffrey M Keil, et al.
Published: (2014-01-01)

Transport Oligonucleotides–a Novel System for Intracellular Delivery Of Antisense Therapeutics
by: Oleg V. Markov, et al.
Published: (2020-08-01)

Rational Design of Short Locked Nucleic Acid-Modified 2′-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro
by: Bao T. Le, et al.
Published: (2017-12-01)

Pediatric Neuromuscular Diseases Prevalence in Siriraj Hospital, Thailand's Largest Tertiary Referral Hospital
by: Apirada Thongsing, et al.
Published: (2020-01-01)

De-duplicating patient records from three independent data sources reveals the incidence of rare neuromuscular disorders in Germany
by: Kirsten König, et al.
Published: (2019-06-01)

Splice-Switching Therapy for Spinal Muscular Atrophy
by: Katharina E. Meijboom, et al.
Published: (2017-06-01)

Antisense Oligonucleotide Gene Therapy for Neuromuscular Disorders
by: Ryan Gotesman
Published: (2018-11-01)

The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery
by: Maria Gagliardi, et al.
Published: (2021-04-01)

Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
by: Karishma Dhuri, et al.
Published: (2020-06-01)

Morpholino Oligomer-Induced Dystrophin Isoforms to Map the Functional Domains in the Dystrophin Protein
by: Dunhui Li, et al.
Published: (2020-12-01)

Current Genetic Survey and Potential Gene-Targeting Therapeutics for Neuromuscular Diseases
by: Wei Chiu, et al.
Published: (2020-12-01)

Antisense Oligonucleotides Conjugated with Lipophilic Compounds: Synthesis and In Vitro Evaluation of Exon Skipping in Duchenne Muscular Dystrophy
by: Bovolenta, M., et al.
Published: (2022)

Antisense Oligonucleotides Conjugated with Lipophilic Compounds: Synthesis and In Vitro Evaluation of Exon Skipping in Duchenne Muscular Dystrophy
by: Bovolenta, M., et al.
Published: (2022)

BACE1 Inhibition Using 2’-OMePS Steric Blocking Antisense Oligonucleotides
by: Madhuri Chakravarthy, et al.
Published: (2019-09-01)

History of Research on Antisense Oligonucleotide Analogs
by: Jack S. Cohen
Published: (2021-03-01)

Dual SMN inducing therapies can rescue survival and motor unit function in symptomatic ∆7SMA mice
by: Kaitlyn M. Kray, et al.
Published: (2021-11-01)